New hope for tough stomach cancer: triple drug attack
NCT ID NCT07507526
First seen Apr 24, 2026 · Last updated Jun 11, 2026 · Updated 10 times
Summary
This study tests a combination of three drugs (disitamab vedotin, tunlametinib, and a PD-1 antibody) in people with advanced stomach cancer that has a specific protein (HER2) and has not responded to at least two prior treatments. The goal is to see if the combo can shrink tumors and how safe it is. Participants receive intravenous infusions every 2 to 6 weeks and take one drug orally twice daily, with regular checkups and scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.